Workflow
Lilly(LLY)
icon
Search documents
Eli Lilly to invest $1 billion in India, expand manufacturing and introduce oral weight-loss drug
The Economic Times· 2025-10-06 18:58
From a billion-dollar investment in In its latest move, the company is making a major investment of over $1 billion over the coming years to bolster its contract manufacturing capabilities in India, it said in an announcement on Monday. Its planned tie-ups with contract manufacturers in India will help expand its "We are making significant investments to increase manufacturing and medicine supply capacity around the world to help ensure patients have access to the medicines," said, Patrik Jonsson, executiv ...
Trump's Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
MarketBeat· 2025-10-06 18:21
When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However, sometimes these price decreases end up attracting new business, expanding market share, and more than making up for the lost ticket price in the top-line revenue. With increased volume and demand, suppliers also receive better deals, which significantly lower costs, among other benefits. Ultimately, a price discou ...
"Exciting Race" Between LLY & NVO, Tariffs Remain Long-Term Overhang
Youtube· 2025-10-06 16:00
We're back on Morning Trade Live. The weight loss drug trade has been a good one over the last two months. After dipping in early August due to subpar earnings, both Eli Lily and Nova Nordisk have moved higher to the tune of more than 30% from those lows.The companies have been battling in the injectable weight loss drug market over the last few years, and all versions of the drugs are expected to hit the market before the end of the year. So, let's go inside out on the weight loss drug trade. joining us no ...
Eli Lilly: Beyond Weight Loss
Yahoo Finance· 2025-10-06 13:56
Key Points Mounjaro and Zepbound have helped boost the company's market cap. New data indicate these drugs do more than just help patients lose weight, contributing to potentially lowering risks to hearts and kidneys. Despite a high stock price, Lilly's strong returns and cash-flow generation demonstrate it's worth paying up for. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) is now known for its weight loss drugs. Its stock has risen 150% since mid-2022 because of high demand for ...
礼来(LLY.US)拟在印度投资逾10亿美元 以提升减肥药等关键药物产能
Zhi Tong Cai Jing· 2025-10-06 10:47
Core Viewpoint - Eli Lilly (LLY.US) plans to invest over $1 billion in India over the next few years to enhance its production and supply network through local pharmaceutical companies, aiming to support its global manufacturing expansion and improve the supply capacity of key drugs for obesity, diabetes, Alzheimer's, cancer, and autoimmune diseases [1] Group 1: Investment Plans - The investment is part of a broader strategy to build global manufacturing and drug supply capabilities, with India identified as a crucial hub in this network [1] - Eli Lilly has previously announced a $5 billion investment to build a new factory in Virginia, as part of a $27 billion expansion plan that includes four new factories in the U.S. over the next five years [1] Group 2: Market Dynamics - The launch of Mounjaro in India, alongside Novo Nordisk's Wegovy, has significantly increased awareness of obesity treatment among Indian patients, with sales of both drugs doubling within months of their release [2] - Eli Lilly is preparing to face intensified competition from Indian generic drug companies, particularly with the impending expiration of the patent for semaglutide, the active ingredient in Wegovy [2] Group 3: Manufacturing and Quality Center - The company is establishing a new manufacturing and quality center in Hyderabad, which will oversee its contract manufacturing network in India and provide technical support [3] - Recruitment for various positions, including engineers, chemists, and quality control experts, has already begun to support the localization of its global supply chain strategy [3]
The Healthcare Stock Play That Could Make Millennials Rich
Yahoo Finance· 2025-10-06 09:54
Key Points This investment has averaged annual gains of close to 13% over the past 15 years. It encompasses many healthcare stocks -- including superperformer Eli Lilly. It's a promising investment if you're bullish on the healthcare sector. 10 stocks we like better than Vanguard World Fund - Vanguard Health Care ETF › If a millennial were to ask me what healthcare stock they might buy in order to get rich, I could think of several to name. But as with most stocks, I couldn't be confident that ...
Eli Lilly to inject $1 billion in new contract manufacturing facilities in India; to set up new manufacturing & quality hub in Hyderabad
The Times Of India· 2025-10-06 08:45
Core Insights - Eli Lilly will invest over $1 billion in new contract manufacturing facilities in India, establishing a new manufacturing and quality hub in Hyderabad [2][3] - The investment aims to enhance Lilly's supply capabilities and leverage India's skilled talent pool to support global manufacturing growth [3][4] - Since 2020, Lilly has committed over $55 billion to build, expand, and acquire facilities globally, focusing on new medicines for diabetes, obesity, Alzheimer's, cancer, and autoimmune conditions [2][3] Company Strategy - The new hub in Hyderabad will provide advanced technical capabilities and oversight for Lilly's contract manufacturing network across India [2][3] - Immediate recruitment will begin for various roles, including engineers, chemists, analytical scientists, and quality control professionals [2][3] - The investment reflects Lilly's confidence in India as a key location for capability building within its global network [3][4] Regional Impact - Telangana's officials view Lilly's expansion as a validation of the state's emergence as a global healthcare innovation hub [4] - The state's focus on technology-driven infrastructure and ease of doing business is attracting global leaders, particularly in the life sciences sector [4] - Lilly's existing commercial site in Gurugram and specialized sites in Bengaluru and Hyderabad support global innovation and are being reinforced through strategic investments [4]
Eli Lilly to invest over $1 billion in India to expand manufacturing capacity
Reuters· 2025-10-06 07:12
Eli Lilly will invest more than $1 billion in India in the coming years to boost manufacturing and supply through local drugmakers, the company said on Monday, as it seeks to tap into skilled workforc... ...
Jim Cramer Highlights Eli Lilly’s Drug Potential Beyond Diabetes and Obesity
Yahoo Finance· 2025-10-04 21:01
Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer put under the microscope. Cramer highlighted the importance of the company’s GLP-1 drug, as he stated: “I suggest, for example, that you consider Eli Lilly because of its remarkable GLP-1 diabetes and weight loss drug. Those are the most obvious uses. But when this year is over, I gotta tell you something, I think it could be used for everything from the silent killer of hypertension to dementia, and yes, alcoholism. Lilly’s stock has been s ...
速递|风靡全球!去年四分之一的美国糖尿病患者使用了GLP-1药物
GLP1减重宝典· 2025-10-04 05:21
整理 | GLP1减重宝典内容团队 美国疾病控制与预防中心(CDC)周四表示,去年超过四分之一的美国成年人糖尿病患者使用过针对GLP-1蛋白的注射类药物。 这些广受欢迎且疗效显著的GLP-1药物,包括礼来公司的Mounjaro和诺和诺德的Ozempic,已在美国获批用于治疗2型糖尿病。同时, 它们分别以Zepbound和Wegovy的名称销售用于减重,并正被测试用于其他疾病。 报告显示,使用比例最高的是50至64岁的糖尿病成年人,达到33.3%,反映出该年龄段疾病负担较重。18至34岁人群的使用率为 25.3%,65岁及以上人群为20.8%。 数据来自2024年进行的一项全国性年度调查,涵盖18岁及以上成年人。调查先进行面对面访谈,再通过电话回访。2024年首次向糖尿 病受访者询问是否使用礼来或诺和诺德的畅销药物,或其他GLP-1药物来控制血糖或减重。 GLP-1药物通过模拟调节血糖水平的激素作用,延缓消化,并延长饱腹感。礼来和诺和诺德因药物价格高昂而遭到批评,这类药物一 个月的标价约为1,000美元。 调查还显示,约31%的胰岛素使用者同时使用GLP-1药物;在口服降糖药患者中,这一比例约为28%,说明GL ...